Media stories about MannKind (NASDAQ:MNKD) have trended somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. MannKind earned a daily sentiment score of 0.04 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.0386336293314 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
- The Simple Reason Why I Won't Buy MannKind Corporation Stock (finance.yahoo.com)
- The Simple Reason Why I Won’t Buy MannKind Corporation Stock (fool.com)
- MannKind Co. (MNKD) Receives Consensus Rating of “Hold” from Brokerages (americanbankingnews.com)
- Hot Stock to Track – MannKind Corporation (NASDAQ: MNKD) – Alpha Beta Stock (alphabetastock.com)
- MannKind Corporation to Present at NobleCon14 – Noble Capital Markets’ Fourteenth Annual Investor Conference (finance.yahoo.com)
A number of equities research analysts have recently commented on the stock. HC Wainwright assumed coverage on shares of MannKind in a report on Tuesday, October 10th. They set a “buy” rating on the stock. ValuEngine downgraded shares of MannKind from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 14th. Zacks Investment Research upgraded shares of MannKind from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. BidaskClub downgraded shares of MannKind from a “hold” rating to a “sell” rating in a research report on Friday, December 22nd. Finally, Maxim Group restated a “hold” rating on shares of MannKind in a research report on Wednesday, November 1st. Four equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $0.92.
MannKind (NASDAQ:MNKD) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.11). The company had revenue of $2.04 million for the quarter, compared to the consensus estimate of $2.56 million. MannKind had a negative net margin of 155.83% and a negative return on equity of 24.93%. The firm’s revenue for the quarter was down 98.7% on a year-over-year basis. During the same quarter last year, the company earned $1.30 EPS. equities research analysts predict that MannKind will post -1.13 earnings per share for the current fiscal year.
In related news, VP Stuart A. Tross acquired 39,840 shares of the stock in a transaction that occurred on Thursday, December 21st. The shares were bought at an average price of $2.52 per share, for a total transaction of $100,396.80. Following the completion of the transaction, the vice president now directly owns 59,840 shares in the company, valued at $150,796.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.10% of the stock is owned by corporate insiders.
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.